Physician profile
Veronica Garner
NPI 1508467945
$4,408.25
in general payments reported to CMS, 2019-2025
16 companies · $922 in 2025
The $922 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,636 · 2023: $1,071 · 2024: $779 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $978.67 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $614.48 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $493.26 | 2023-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $405.38 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Teva Pharmaceuticals USA, INC. | $332.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $292.81 | 2022-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.15 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $204.01 | 2022-2025 | |
| Lundbeck LLC | $183.01 | 2022-2025 | Rexulti, Abilify Maintena |
| Jazz Pharmaceuticals INC. | $125.40 | 2022 | |
| Almatica Pharma LLC | $124.59 | 2022-2025 | Gralise, Loreev Xr |
| Noven Therapeutics, LLC | $110.85 | 2024-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $97.05 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $86.51 | 2022-2023 | Qelbree |
| Alkermes, INC. | $86.41 | 2022-2023 | Aristada, Lybalvi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $31.83 | 2024-2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.